iSPERSE technology

June 30, 2016June 30, 2016

Lung Disease, New Inhaled Treatments by Pulmatrix Described in Animated Science Video

Asthma, COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

A life sciences animated video was recently released by Pulmatrix to explain breathing issues experienced by patients with serious lung diseases and to illustrate novel promising therapies developed by the company. The ... Read more

February 23, 2016May 13, 2016

Capsugel and Pulmatrix Partnering to Develop Inhaled Therapeutics for Range of Lung Diseases

COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

Capsugel and Pulmatrix, Inc., entered a partnership to advance the development and manufacture of inhaled therapeutics to treat serious pulmonary diseases, based on Pulmatrix’s iSPERSE technology. “This collaboration provides us with ... Read more

February 4, 2016May 12, 2016

European Clinical Trial Enrolling Patients for COPD Treatment

COPD, News

Pulmatrix Inc., a clinical stage biopharma dedicated to the development of inhaled therapies to address serious pulmonary diseases, recently announced that its European pilot bioequivalence study on PUR0200 for the ... Read more

July 24, 2015November 6, 2015

Pulmatrix Acquires Two More Patents for iSPERSE Technology For Pulmonary Disease Treatments

Asthma, News

Pulmatrix, Inc., a clinical stage biopharmaceutical company focused on developing inhaled therapies to address serious pulmonary diseases, has announced the award of 2 new patents (U.S. Patent # 8,992,983 and U.S. patent # 9,061,352) from the ... Read more